Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Key claim: A Phase I 3+3 trial is evaluating the safety and feasibility of CD4-directed CAR-T cell therapy (CD4CAR) as a second-line treatment for relapsed or refractory CMML.
Abstract
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
Why this matters
CMML’s defining monocytic biology has motivated CSF-1R-directed approaches (axatilimab), but CD4CAR represents the first adoptive cellular immunotherapy entering the CMML salvage landscape, exploiting CD4 expression on malignant monocytes. If feasibility and safety are established, this would open a fundamentally new mechanistic class for relapsed/refractory CMML — a subtype where second-line options after HMA failure remain severely limited and where transformation risk drives urgency for novel modalities.